Lavipharm Sa Stock Current Asset
| LAVI Stock | EUR 0.73 0.01 1.39% |
Lavipharm SA fundamentals help investors to digest information that contributes to Lavipharm's financial success or failures. It also enables traders to predict the movement of Lavipharm Stock. The fundamental analysis module provides a way to measure Lavipharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lavipharm stock.
Lavipharm |
Lavipharm SA Company Current Asset Analysis
Lavipharm's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Lavipharm Current Asset | 21 M |
Most of Lavipharm's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lavipharm SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Lavipharm SA has a Current Asset of 21 M. This is 99.02% lower than that of the Healthcare sector and 99.85% lower than that of the Drug Manufacturers - Major industry. The current asset for all Greece stocks is 99.78% higher than that of the company.
Lavipharm Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lavipharm's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lavipharm could also be used in its relative valuation, which is a method of valuing Lavipharm by comparing valuation metrics of similar companies.Lavipharm is currently under evaluation in current asset category among its peers.
Lavipharm Fundamentals
| Return On Asset | 0.0403 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 59.98 M | |||
| Shares Outstanding | 18.29 M | |||
| Shares Owned By Insiders | 67.47 % | |||
| Price To Earning | 12.42 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 41.37 M | |||
| Gross Profit | 15.89 M | |||
| EBITDA | 4.72 M | |||
| Net Income | 1.72 M | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 40.54 M | |||
| Current Ratio | 1.29 X | |||
| Book Value Per Share | (0.47) X | |||
| Cash Flow From Operations | 3.82 M | |||
| Earnings Per Share | 0.04 X | |||
| Beta | 0.66 | |||
| Market Capitalization | 8.56 M | |||
| Total Asset | 82 M | |||
| Retained Earnings | (181 M) | |||
| Working Capital | (66 M) | |||
| Current Asset | 21 M | |||
| Current Liabilities | 87 M | |||
| Z Score | -2.8 | |||
| Five Year Return | 4.13 % |
About Lavipharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lavipharm SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lavipharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lavipharm SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.